Abstract

MicroRNAs are small ribonucleic acid that act as an important regulator of gene expression at the molecular level. However, there is no comparative data on the regulation of microRNAs (miRNAs) in visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). In this current study, we compared the expression miRNA profile in host cells (GTHP), with VL strain (GVL) and PKDL strain-infected host cell (GPKDL). Normalized read count comparison between different conditions revealed that the miRNAs are indeed differentially expressed. In GPKDL with respect to GVL and GTHP, a total of 798 and 879 miRNAs were identified, out of which 349 and 518 are known miRNAs, respectively. Comparative analysis of changes in miRNA expression suggested that the involvement of differentially expressed miRNAs in various biological processes like PI3K pathway activation, cell cycle regulation, immunomodulation, apoptosis inhibition, different cytokine production, T-cell phenotypic transitions calcium regulation, and so on. A pathway enrichment study using in silico predicted gene targets of differentially expressed miRNAs showed evidence of potentially universal immune signaling pathway effects. Whereas cytokine–cytokine receptor interaction, phagocytosis, and transforming growth factor beta (TGF-β) signaling pathways were more highly enriched using targets of miRNAs upregulated in GPKDL. These findings could contribute to a better understanding of PKDL pathogenesis. Furthermore, the identified miRNAs could also be used as biomarkers in diagnosis, prognosis, and therapeutics of PKDL infection control.

Highlights

  • Visceral leishmaniasis (VL) is a vector-borne disease caused by an intracellular parasite, Leishmania donovani

  • Infection was confirmed by Giemsa staining (Merck) in GVL and GPKDL infection compared to the GTHP groups

  • We have, for the first time, shown the unique microRNA that is exclusively differentially expressed in human macrophage THP-1 cell line after infection with L. donovani isolated from post-kala-azar dermal leishmaniasis (PKDL) patients (GPKDL) compared with uninfected THP-1 (GTHP) and THP-1 infected with L. donovani isolated from visceral leishmaniasis patients (GVL) by NGS and their role in immunological pathway regulation

Read more

Summary

Introduction

Visceral leishmaniasis (VL) is a vector-borne disease caused by an intracellular parasite, Leishmania donovani. The highest burden of VL is reported from the states of Bihar, Jharkhand, West Bengal, and Uttar Pradesh of India. 90% of VL cases in India originate from Bihar (Singh et al, 2010). Post-kalaazar dermal leishmaniasis (PKDL), an enigmatic dermal sequel of VL, may appear after treatment of (VL, kala-azar) (Zijlstra et al, 2000). Several cases have been reported without a documented history of VL in 10–23% of patients (Zijlstra et al, 2017). It calls for better management of PKDL, especially susceptibility

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call